Drug intelligence / Profile preview

BM-501

Development stage: Preclinical
Lead developer: Biomea Fusion
Modality: Small Molecules

Overview

BM-501 is a preclinical-stage irreversible small molecule inhibitor developed by Biomea Fusion. It is designed to target oncogenic KRAS mutants for the treatment of genetically defined cancers. Biomea Fusion is a biopharmaceutical company focused on developing therapeutics for genetically defined cancers and raised capital through an IPO to advance its pipeline, including BM-501, into clinical trials.

Targets

KRAS (Kirsten rat sarcoma viral oncogene homolog)

Beyond the preview

Go deeper on BM-501.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BM-501.

Explore the full profile